Postoperative Symptoms in Chinese Liver Cancer Patients: Network Analysis
Launched by MENGMENG YUAN · May 14, 2024
Trial Information
Current as of March 14, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Eligible patients were ≥18 years of age; had a diagnosis of primary liver cancer based on pathologic examination; were receiving the first hepatectomy; were conscious, spoke Chinese, and had basic communication skills.
- Exclusion Criteria:
- • Exclusion criteria include concurrent malignant tumors, mental disorders, or consciousness impairments, as well as participation in other clinical interventions.
Trial Officials
shuwen M Li, PhD
Study Chair
Anhui Medical University
About Mengmeng Yuan
Mengmeng Yuan is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on rigorous scientific methodology and ethical standards, Mengmeng Yuan collaborates with healthcare professionals and research institutions to design and execute clinical trials that address unmet medical needs. By leveraging cutting-edge technology and a patient-centric approach, the organization aims to expedite the development of safe and effective treatments, ultimately contributing to the enhancement of global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hefei, Anhui, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
